RITALIN LA
Clinical safety rating
cautionComprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
| Metabolism | Primarily hepatic via deesterification to ritalinic acid (inactive). CYP2D6 plays a minor role. |
| Excretion | Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2% |
| Half-life | Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation |
| Protein binding | 10–15% (primarily to albumin) |
| Volume of Distribution | 2.65 L/kg (likely higher due to extensive tissue distribution; reflects wide distribution into brain and other tissues) |
| Bioavailability | Oral: 22–25% (racemic); d-enantiomer higher due to stereoselective first-pass metabolism |
| Onset of Action | Oral (LA capsule): 1–2 hours (initial peak); biphasic release with second peak at 4–5 hours |
| Duration of Action | 8–12 hours; clinical note: designed for once-daily dosing with less rebound than immediate-release |
| Molecular Weight | 329.82 |
20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased exposure. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B or C: reduce dose by 50% or use alternative. |
| Pediatric use | Children 6-12 years: 20-40 mg orally once daily in the morning; maximum 60 mg/day. Adolescents: same as adult dosing. |
| Geriatric use | Initiate at lowest effective dose (20 mg/day); monitor for hypertension, tachycardia, and appetite suppression. Consider alternative if comorbid conditions present. |
| 1st trimester | Methylphenidate is not recommended in first trimester due to lack of safety data and potential for teratogenicity. Limited human studies show a possible increased risk of congenital malformations, particularly cardiac defects, although absolute risk remains low. Animal studies have shown fetal harm at high doses. |
| 2nd trimester | Use only if potential benefit justifies risk. There is limited data; however, methylphenidate may cross placenta and affect fetal growth. Monitor fetal development closely. |
| 3rd trimester | Use near term may increase risk of neonatal toxicity (e.g., irritability, feeding difficulties). Avoid use in late pregnancy unless clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for RITALIN LA (RITALIN LA).
| Placental transfer | Methylphenidate crosses the placenta. Fetal-maternal ratios have not been well established in humans, but animal studies indicate transfer. |
| Breastfeeding | Methylphenidate is excreted into breast milk in small amounts (relative infant dose about 0.2-2.3% of maternal weight-adjusted dose). Peak milk concentrations occur 1-3 hours after dosing. No adverse effects have been reported in breastfed infants, but caution is advised, especially in preterm or ill infants. Monitor infant for irritability, insomnia, and poor weight gain. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second/third trimester: Possible increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, dysphoria) with chronic use. Avoid unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain. Fetal ultrasound for growth and amniotic fluid index. Neonatal monitoring for withdrawal symptoms (irritability, hypertonia, feeding difficulties) post-delivery. |
| Fertility Effects | No human data on fertility. Animal studies show no impairment of fertility at clinically relevant doses. Potential impact due to CNS stimulant effects on libido or hormonal regulation is theoretical. |
■ FDA Black Box Warning
RITALIN LA has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
Marked anxiety, tension, or agitationGlaucomaTics or family history of Tourette syndromeConcurrent use of MAOIs or within 14 days of discontinuationHypersensitivity to methylphenidate or any excipientSevere hypertensionHeart failure, recent myocardial infarction, or serious structural cardiac abnormalities
| Precautions | Serious cardiovascular events: Sudden death in patients with structural cardiac abnormalities or other serious heart problems., Psychiatric adverse events: Exacerbation of pre-existing psychosis, mania, or aggression., Seizures: Use with caution in patients with history of seizures., Growth suppression: Monitor growth during treatment., Hematologic effects: Monitor for leukopenia, anemia, thrombocytopenia., Peripheral vasculopathy: Raynaud's phenomenon., Long-term suppression of growth., Visual disturbances: Blurred vision. |
| Food/Dietary | No specific food restrictions. However, high-fat meals may delay absorption and reduce peak concentration slightly. Consistent dosing with respect to meals is recommended. Avoid high vitamin C intake within 1 hour before or after dosing as it may decrease absorption. Grapefruit juice has not been studied but theoretically may affect metabolism; advise moderation. |
| Clinical Pearls | Ritalin LA is a long-acting methylphenidate formulation using SODAS (Spheroidal Oral Drug Absorption System) technology. It provides bimodal release with an initial immediate-release component followed by a delayed-release pulse approximately 4 hours post-dose. Avoid crushing or chewing capsules; can sprinkle contents on applesauce for patients with swallowing difficulties. Duration of action is approximately 8 hours. Monitor for blood pressure and heart rate changes; contraindicated in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use with caution in patients with pre-existing psychosis, bipolar disorder, or substance abuse history. |
| Patient Advice | Take Ritalin LA exactly as prescribed, usually once daily in the morning. Do not take it later in the day as it may cause insomnia. · Swallow the capsule whole with liquid. If you cannot swallow the capsule, you may open it and sprinkle the contents on a spoonful of applesauce, then immediately consume without chewing. · Avoid alcohol while taking Ritalin LA, as it may alter the release mechanism and increase side effects. · This medication can be habit-forming; do not share it with others and store it securely. · Report any signs of heart problems such as chest pain, shortness of breath, or fainting; also report any new or worsening mental symptoms like anxiety, agitation, or hallucinations. · Common side effects include decreased appetite, trouble sleeping, headache, and stomach upset. These may improve over time. |
Loading safety data…